" class="no-js "lang="en-US"> Olive Hits a $4 Billion Valuation with $400 Million of Capital Led by Vista Equity Partners - Medtech Alert
Thursday, May 23, 2024

Olive Hits a $4 Billion Valuation with $400 Million of Capital Led by Vista Equity Partners

Olive, the automation company creating the Internet of Healthcare, announced today it closed a $400 million funding round, bringing the company to a $4 billion valuation. The round was led by Vista Equity Partners (“Vista”), a leading global investment firm focused on enterprise software, data, and technology-enabled businesses, with additional investment from the Base10 Partners Advancement Initiative. As a Base10 Advancement Initiative portfolio company, Olive will contribute to scholarship and financial aid awards for America’s Historically Black Colleges and Universities, which will become known as The Olive Scholarship.

Olive’s AI workforce connects patients, providers and payers to automate burdensome workflows and support human workforces, and has been a catalyst for healthcare’s pace of digital transformation pulling ahead of other industries. A recent McKinsey study, “The State of AI in 2020,” found that healthcare was the top industry adopting AI. This latest round of funding will allow Olive to further scale product development, reaching more healthcare providers who can use Olive’s technology to drive life-changing outcomes. Olive has now secured $832 million in financing since March 2020, and $902 million since the company’s inception in 2012.

“Olive is the leading force for rapid product development to better empower the humans in healthcare. She is being hired at health systems and insurance companies across the country at lightning speed,” said Sean Lane, CEO of Olive. “Olive’s widespread adoption as mission-critical tech makes it clear that now is the time for the healthcare industry to pull into the lead position for enterprise AI adoption.”

“At Vista, we believe in the transformative power of technology and see incredible potential in Olive’s ability to connect healthcare providers in new ways,” said Monti Saroya, Co-Head of Vista’s Flagship Fund and Senior Managing Director. “We believe the company’s AI capabilities are poised to deliver true disruption to the healthcare industry through automating and optimizing workflows, improving interoperability and turning critical data into actionable insights. We look forward to working closely with Olive’s management team as they continue to execute on their vision.”

Olive’s enterprise AI is now in place at more than 900 hospitals in over 40 U.S. states, including more than 20 of the top 100 U.S. health systems. To drive true transformation Olive is leveraging network efforts as it connects healthcare, delivering constantly growing intelligence across the industry through a series of new products, as well as acquisitions and a platform that developers are able to build off of.

Olive doubles down on innovation and expanding its ecosystem to transform healthcare

Since the company’s most recent valuation of $1.5 billion in December 2020, Olive strengthened its position in the clinical intelligence space with its acquisition of Empiric Health and took aim at accelerating the provider payments process with Olive Assures. This month, the company is making available Olive Helps, healthcare’s superhuman sidekick that improves the speed, quality and impact of healthcare workers, as a free download to the public. Additionally, the company is opening its software to a community of developers – from individuals to companies large and small – with the goal of making it the first true platform for healthcare. Its developer’s kit, called the “Loop Development Kit,” is available for anyone to get their solutions in front of the nation’s leading healthcare users and help be part of the technology community transforming healthcare.

Hiring talent from across the country on a flexible “Grid” model

To enable these new product developments, funding will also be used to recruit new talent across the country as Olive rapidly scales its product, data and engineering talent, among other roles. Over the course of 2021, Olive is expected to more than double its number of employees. The company has a flexible workforce model called “The Grid” that launched in May 2020 and was recommitted to recently with Olive empowering employees to live and work wherever they choose. When The Grid model launched about a year ago Olive had approximately 230 employees in less than 20 states. The company now has approximately 800 employees spread across 43 states.

To learn more about Olive, visit www.oliveai.com. For open roles please visit https://oliveai.com/careers/. 

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more